Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients.
It has been demonstrated that prolonged in vivo or in vitro treatment with some nucleosides analogs may favor the selection of cells with a reduced activity of enzymes involved in the phosphorylation of these drugs leading to a reduced sensitivity to their antiretroviral action. The aim of this study was to evaluate the effect, in vivo, of zidovudine and stavudine treatment on thymidine kinase (TK) activity. The results obtained showed that TK levels in PBMC from naive patients and stavudine-treated patients did not significantly differ (naive TK = 4.16 +/- 1.19 U/mg protein; stavudine TK = 3.65 +/- 1.73 U/mg protein; p = 0.42), suggesting that the treatment with this nucleoside analog is not associated to a defect of TK activity. On the contrary, PBMC from zidovudine-treated patients showed a significant reduction in TK activity compared to naive patients (naive TK = 4.16 +/- 1.19 U/mg protein; zidovudine TK = 2.70 +/- 1.54; p = 0.014. Although the clinical significance of these results has to be established, we can speculate that stavudine and zidovudine, which are presumably phosphorylated by the same cellular kinases, might display a different ability to in vivo select cells with a resistant phenotype.
Department of Experimental Medicine and Pathology-Virology Section, University "La Sapienza," 00185 Rome, Italy.
Ombretta
O
Turriziani
Nicola
N
Gianotti
Federica
F
Bambacioni
Paolo Emilio
PE
Manconi
Adriano
A
Lazzarin
Guido
G
Antonelli
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000201:enzymology; D018119:Stavudine / Q000627:therapeutic use*; D013937:Thymidine Kinase / Q000097:blood* / Q000187:drug effects; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine; D018119:Stavudine; D013937:Thymidine Kinase